title: Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.
abstract: OBJECTIVE
  To evaluate in vivo whether the expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of the telomerase complex, is predictive of response to chemotherapy in ovarian cancer patients.
  
  
  METHODS
  Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied. hTERT levels were evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) on tumor specimens obtained before the treatment. Variables were analyzed by the chi(2) and Fisher's exact tests. Logistic regression analysis was also performed to account for the effects of all the covariates investigated (residual disease, stage, histotype, and grade).
  
  
  RESULTS
  Twenty-eight (47%) of the 59 tumors showed low hTERT levels, whereas 31 (53%) tumors displayed high hTERT levels. Seventy-five percent of complete responders showed high levels of hTERT expression, whereas 66% of partial responders or nonresponders exhibited low hTERT levels (P =.002). Only residual disease and hTERT expression were independent predictors of response (odds ratios, 13.455 and 7.586, respectively). The combination of these two parameters provides powerful predictive information: 18 of the 20 patients with residual disease more than 2 cm and low hTERT levels were partial responders or nonresponders, whereas 11 of the 12 patients with residual disease less than 2 cm and high hTERT levels showed a complete response (chi(2) = 21,416; P <.00001).
  
  
  CONCLUSIONS
  Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients. Prospective validation of this marker will be required to further define its predictive value.
authors.affiliation: Department of Oncology and Neurosciences, University of Chieti, Italy. fbuttitta@unich.it
authors.forename: Fiamma
authors.initials: F
authors.lastname: Buttitta
authors.forename: Caterina
authors.initials: C
authors.lastname: Pellegrini
authors.forename: Antonio
authors.initials: A
authors.lastname: Marchetti
authors.forename: Angiolo
authors.initials: A
authors.lastname: Gadducci
authors.forename: Stefania
authors.initials: S
authors.lastname: Cosio
authors.forename: Lara
authors.initials: L
authors.lastname: Felicioni
authors.forename: Fabio
authors.initials: F
authors.lastname: Barassi
authors.forename: Simona
authors.initials: S
authors.lastname: Salvatore
authors.forename: Carla
authors.initials: C
authors.lastname: Martella
authors.forename: Guido
authors.initials: G
authors.lastname: Coggi
authors.forename: Silvano
authors.initials: S
authors.lastname: Bosari
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin; D003520:Cyclophosphamide / Q000008:administration & dosage; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019098:Telomerase / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D003520:Cyclophosphamide; D019098:Telomerase; D002945:Cisplatin